We are live on ! Find out more
IBB icon

iShares Biotechnology ETF
IBB

232 hedge funds and large institutions have $2.26B invested in iShares Biotechnology ETF in 2013 Q2 according to their latest regulatory filings, with 232 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

39% less call options, than puts

Call options by funds: $129M | Put options by funds: $213M

Holders
232
Holders Change
+232
Holders Change %
–
% of All Funds
7.54%
Holding in Top 10
10
Holding in Top 10 Change
+10
Holding in Top 10 Change %
% of All Funds
0.33%
New
232
Increased
–
Reduced
–
Closed
–
Calls
$129M
Puts
$213M
Net Calls
-$84.1M
Net Calls Change
-$84.1M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

IBB Hedge Fund Activity: Q2 2013 in Review

232 of the 3,075 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2013, worth a combined $2.26B.

Buyers outnumbered sellers: 232 funds opened new IBB positions and 0 closed out — a net gain of 232 holders — while 0 added to existing stakes and 0 trimmed.

  • 232 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $2.26B of iShares Biotechnology ETF stock for Q2 2013.
  • 232 funds opened new iShares Biotechnology ETF positions in Q2 2013 and 0 closed out, a net change of +232 holders.

Based on aggregated 13F filings for Q2 2013.